Enterprise record

Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:2150d703-233d-4995-a080-b1bc3fc4ec98Version: public-1As of: unavailable

14 published Claims4 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 29, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 3 claims
    • Legal Name: Aptevo Therapeutics Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026

  2. Aptevo Therapeutics Inc. DEF 14A 2026-07-31

    sec proxy · Source published: Jul 31, 2026 · Retrieved: Sep 2, 2026

    Supports 4 claims
    • Leadership Role: Barbara Lopez Kunz: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Daniel J. Abdun-Nabi: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Grady Grant, III: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Marvin L. White: Director · Claim reviewed: Sep 29, 2026

  3. SEC DEF 14A 0001193125-26-376763

    sec def 14a · Source published: Aug 31, 2026 · Retrieved: Sep 5, 2026

    Supports 5 claims
    • Leadership Role: Jeffrey G. Lamothe: President, Chief Executive Officer and Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: John E. Niederhuber, M.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Zsolt Harsanyi, Ph.D.: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jeffrey G. Lamothe: President and Chief Executive Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: SoYoung Kwon: SVP, General Counsel, Business Development and Corporate Affairs · Claim reviewed: Sep 29, 2026

  4. APVO 10-K executive officers

    sec filing · Source published: Mar 26, 2026 · Retrieved: May 15, 2026

    Supports 2 claims
    • Leadership Role: Daphne Taylor: Senior Vice President, Chief Financial Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Marvin L. White: President and Chief Executive Officer · Claim reviewed: Sep 29, 2026